Highly active antiretroviral therapy has substantially improved the outlook for persons with HIV, and the combination of clinical trial data and experience has provided guidance for the best use of highly active antiretroviral therapy to balance efficacy, safety, tolerability, and adherence. The nonnucleoside reverse transcriptase inhibitors (NNRTIs) and several of the boosted protease inhibitors (PIs, eg, lopinavir/ritonavir) have shown high levels of viral suppression and CD4 count increases as initial therapy. Preliminary evidence suggests that NNRTI regimens may be more forgiving of certain levels of nonadherence than PIs. The evidence also shows that not all agents or combinations of agents are appropriate for all HIV patients. Patient factors such as lipids and triglycerides, hyperglycemia/diabetes, renal function, weight, gender, probability of and desire for pregnancy, initial CD4 count, race, and mental health status will all need to be considered to select the best therapy for the individual.
Twenty-six years after the first descriptions of acquired immunodeficiency due to the human immunodeficiency virus (HIV), 1 there are many approved agents in 4 different antiretroviral classes. Indeed, combination antiretroviral therapy has drastically decreased the morbidity and mortality associated with HIV infection in populations where antiretroviral agents are readily available. 2, 3 But, how can patients newly initiated on highly active antiretroviral therapy (HAART) maximize their chances of treatment success, and what does treatment success mean for the individual patient?
Virologic and Immunologic Response
Obviously, a key requirement for any definition of success is successful suppression of the virus. A plethora of randomized clinical trials over the past decade have been performed comparing various combinations of agents and have successively defined increasingly higher levels of virologic suppression. 4 An early study of indinavir with 2 nucleoside reverse transcriptase inhibitors (NRTIs) in patients without previous lamivudine or protease inhibitor (PI) treatment demonstrated significantly decreased progression to AIDS or death; 60% of a small randomly selected sample of patients in the indinavir arm had HIV-1 RNA <500 copies/mL at 24 weeks. 5 Subsequently, introduction of nonnucleoside reverse transcriptase inhibitors (NNRTIs) and better-tolerated PIs demonstrated even higher rates of virologic suppression for prolonged periods of time. DMP 006 established that efavirenz with lamivudine and zidovudine was superior to indinavir with lamivudine and zidovudine; the intent-to-treat analysis showing 64% of patients with virologic suppression (<50 copies/mL), compared with 43% in the indinavir arm at week 48. 6 Subsequent follow-up has demonstrated durability of this efavirenz regimen, with 42% of patients treated with efavirenz + lamivudine + zidovudine remaining virologically suppressed (HIV RNA <50 copies/mL) after more than 3 years. 7 There have been few trials comparing efficacy of the most commonly used NNRTI agents, nevirapine and efavirenz. However, the 2NN trial sought to establish equivalence of nevirapine and 2 NRTIs compared with efavirenz and 2 NRTIs in antiretroviral treatment-naive HIV-infected patients. 8 Trial design incorporated 4 arms in which stavudine and lamivudine served as the nucleoside backbone for each arm: once-daily nevirapine, twice-daily nevirapine, efavirenz, and nevirapine + efavirenz. The primary end point was a composite end point for treatment failure that included any of the following: <1 log drop in HIV-1 viral load by week 12, HIV-1 RNA viral load ≥50 copies/mL on 2 consecutive measurements from week 24 onward, treatment regimen change, and death or HIV disease progression. Noteworthy in this trial was the novel treatment regimen of efavirenz + nevirapine, which resulted in treatment failure in 53.1% of patients, compared with 43.6% in patients on daily nevirapine, 43.7% on twice-daily nevirapine, and 37.8% in the efavirenz arm. Although the primary end point was similar in all 3 traditional regimen arms, the trial failed to establish equivalence of the nevirapine twice daily + 2 NRTIs to the control efavirenz + 2 NRTIs arm. Proportions of patients with HIV-1 RNA <50 copies/mL at week 48 were significantly different among the arms: 62.7% for nevirapine + efavirenz, 65.4% for twice-daily nevirapine + 2 NRTIs, 70% for both efavirenz + 2 NRTIs and for once-daily nevirapine + 2 NRTIs. 8 Similar CD4 count increases were observed among the 4 arms. More recently, Adult AIDS Clinical Trials Group (ACTG) 5142 compared lopinavir + ritonavir (given twice daily) and 2 NRTIs with efavirenz + 2 NRTIs in antiretroviral treatment-naive HIV-1 infected patients. In addition, a second experimental arm consisting of efavirenz + lopinavir/ritonavir was assessed. There was a shorter time to virologic failure in the lopinavir/ritonavir + 2 NRTIs arm compared with the efavirenz + 2 NRTIs arm, and a significantly greater proportion of patients had HIV-1 RNA <50 copies/mL at 96 weeks in the efavirenz + 2 NRTIs arm (89%) compared with lopinavir/ritonavir + 2 NRTIs arm (77%). 9 Interestingly, patients in the lopinavir/ritonavir + 2 NRTIs arm had significantly greater CD4 count increases (285 cells) at 96 weeks than those in the efavirenz + 2 NRTIs arm (241 cells).
Treatment Adherence and Response to HAART
Maximizing treatment success requires adherence to prescribed antiretroviral agents. Patterson and colleagues reported that >95% adherence to antiretroviral therapy was required for optimal virologic suppression by antiretroviral regimens containing PIs without ritonavir boosting in NRTI-experienced patients. 10 More recently, Bangsberg observed virologic suppression (<400 copies/mL) in patients on NNRTI-containing regimens with 54% to 100% adherence, compared with 95% to 100% adherence required for virologic suppression in patients on unboosted PI-containing regimens. 11 Similar findings were reported in a larger study of 543 patients by Maggiolo et al. Patients on NNRTIs demonstrated a higher mean adherence rate, 93.6% (95% confidence interval [CI], 92.3-94.8]), compared with a mean adherence of 89.9% (95% CI, 87.7-92) for individuals on PIs. 12 Moreover, risk of virologic failure for patients with "gray zone" adherence was less for those on either efavirenz-or nevirapine-containing HAART. In fact, the type of HAART therapy as well as the adherence rate were the only 2 factors significantly associated with virologic failure; those on NNRTIs with adherence rates ≤75% had a virologic failure rate of >10%, compared with those on PI-containing regimens and adherence rates ≤85%, who had a virologic failure rate of >20%. Maggiolo et al also demonstrated that the number of pills and number of daily doses were the only 2 parameters to correlate with adherence rates. Although 100% adherence is always the goal, it is difficult to achieve. NNRTI-containing regimens may be more forgiving than PI regimens in patients with intermediate levels of adherence.
Adverse Events/Toxicity
As larger numbers of effective antiretroviral agents have become available, agent-specific toxicity patterns have emerged that require prudent antiretroviral selection to minimize treatment-related morbidity and mortality. NRTIs have infrequently been associated with lactic acidosis. Risk factors for lactic acidosis include obesity, female sex, and prolonged nucleoside exposure; fatal lactic acidosis has occurred in pregnant women on the combination of stavudine and didanosine. 13 ACTG study 384 clearly demonstrated excess toxicity with the combination of didanosine and stavudine compared with zidovudine and lamivudine, 14 such that didanosine and stavudine are not recommended for use in HAART initiation regimens. 15 Abacavir has been associated with a hypersensitivity reaction consisting of 2 or more of the following signs/symptoms: fever, rash, gastrointestinal symptoms, malaise/fatigue, and respiratory symptoms. However, the risk for developing a hypersensitivity reaction to abacavir may differ depending on the population. Brothers et al recently demonstrated, in a meta-analysis of results from 5 clinical trials, that black patients may have lower rates of hypersensitivity reaction (3.4%) compared with nonblack patients, in whom the incidence averaged across the 5 clinical trials was 7.9%. 16 As presence of the HLA class I allele, HLA-B * 5701, has been associated with an increased risk of developing hypersensitivity reactions on exposure to abacavir, recent US Department of Health and Human Services Guidelines recommend screening for HLA-B * 5701. Individuals with HLA-B * 5701 should not be prescribed abacavir.
When prescribing antiretrovirals, consideration of coexistent morbidities is essential. Although tenofovir has been associated with acute renal failure and Fanconi syndrome, 17 clinical trials have not demonstrated an increased risk for development of renal failure in the tenofovir arms. 18 However, the presence of underlying renal dysfunction should prompt the consideration of alternative agents, and if used in patients with diminished creatinine clearance, the dosage interval should be adjusted 19 and renal function closely monitored.
The 2 most commonly used NNRTIs have distinct side-effect profiles that impact their choice for regimen selection. Nevirapine has been associated with hepatotoxicity (which may be severe and life-threatening) and rash, and it has CD4 guidelines in place for its use. Efavirenz has been associated with CNS side effects, rash, and is pregnancy category D.
Patients receiving nevirapine presenting with nonspecific prodromal signs of hepatitis have progressed to hepatic failure. Controlled clinical trials demonstrated symptomatic hepatic events in 4% of nevirapinetreated patients compared with 1.2% in control arm patients. Risk for hepatotoxicity was greatest in the first 6 weeks of therapy; however, risk continued to be higher in the nevirapine group through 18 weeks of treatment. The hepatotoxicity may be associated with rash, fever, general malaise, fatigue, myalgia, and arthralgia. 20 In those individuals initiating nevirapine, a 14-day lead-in period of dosing with nevirapine 200 mg daily has been shown to decrease rash frequency. 20 A retrospective review of data has demonstrated that men initiating nevirapine with CD4 counts >400 cells/mm 3 have an increased risk of hepatotoxicity; women initiating nevirapine with CD4 counts >250 cells/mm 3 have a 12-fold higher risk of symptomatic hepatotoxicity. Therefore, nevirapine should be avoided in these groups. Men who initiate therapy with a CD4 count of <400 CD4 cells/mm 3 exhibit a 1.2% risk of a symptomatic hepatic adverse events, ~5-fold lower than in those who initiate outside the CD4 guideline. In women initiating therapy with a CD4 count of <250 cells/mm 3 , the risk is 0.9%, ~12fold lower than in those initiating with a CD4 count of >250 cells/mm 3 where the risk is 11.0%. 20 Efavirenz is associated with central nervous system (CNS) side effects. The label for efavirenz reports nervous system adverse events in 52.7% of patients on efavirenz and in 24.6% of patients on comparator treatment; most of these reported adverse events were mild. 21 ACTG study 5095, a randomized, doubleblind control trial investigated 3 different regimens: efavirenz with lamivudine + zidovudine, efavirenz with lamivudine + zidovudine + abacavir, and lamivudine + zidovudine + abacavir. A substudy assessed neuropsychological symptoms in 303 patients. Patients on efavirenz had more symptoms at week 1, but by week 4, there were no significant differences with respect to CNS side effects, and over the course of the study, neuropsychological performance improved in both groups. 22 Six percent of patients in the ACTG 5095 substudy stopped efavirenz due to CNS side effects. Efavirenz has been associated with possible neural tube malformations in fetus/infants exposed to efavirenz in utero, resulting in classification of this agent as pregnancy category D. Pregnancy should be avoided in women receiving efavirenz, and barrier contraception should always be used in combination with other methods of contraception (eg, oral or other hormonal contraceptives). 21 Although clearly traditional risk factors for the development of cardiovascular disease have been demonstrated to be important in HIV-infected patients, the effects of HIV infection and of antiretroviral treatment on lipid profiles has been the subject of extensive study. To put the subject in context, HIV infection affects lipid profiles; total cholesterol, low-density lipoprotein (LDL), and high-density lipoprotein (HDL) are all decreased in HIV infection. 23 Additionally, with disease progression and AIDS, triglyceride levels are increased. 24 In recent years, several studies have demonstrated increases in the incidence of cardiovascular disease, and associations with PI use have been found. 25, 26 In their recent article, the DAD Study Group concludes that the association of myocardial infarction and PI exposure is partly explained by dyslipidemia. 26 The effect of HAART (whether PI-or NNRTI-based) is to increase total cholesterol 27 ; however, effects on various component lipid parameters are highly agent-dependent. One of the common effects of some PIs is elevation of triglyceride, convincingly demonstrated in individuals treated with nelfinavir, lopinavir/ritonavir, and low-dose ritonavir. 28, 29 Studies have demonstrated that individuals treated with unboosted atazanavir 30 do not demonstrate statistically significant triglyceride elevations. In general, effective HAART treatment with virologic control results in an improvement in HDL that is similar across the PI class. Interestingly, other antiretroviral agent classes have also demonstrated differential effects on the lipid profiles of treated patients. The 2NN study investigated many aspects of treatment with regimens based on either nevirapine or efavirenz. One substudy assessed lipid effects of treatment in 706 patients. Over the period of 1 year, patients on a nevirapine-based regimen showed a mean percentage increase in total cholesterol (TC) of 26.9%, a mean increase in HDL of 42.5%, a mean increase in LDL of 35.4%, and a mean increase in triglycerides (TG) of 20.1%. A 4.1% decrease was observed in the ratio of TC:HDL. Patients on an efavirenz-based regimen showed a mean percentage increase in total cholesterol of 31.1%, a mean increase in HDL of 33.7%, a mean increase in LDL of 40.0%, and a mean increase in TG of 49.0%. A 5.9% increase in the ratio of TC:HDL was observed. The differences between the lipid measurements were significant for TC, HDL, and TG. 31 NRTI agents may also have disparate effects on lipid levels. Gilead Sciences study 903, comparing tenofovir to stavudine (efavirenz and lamivudine were the other HAART agents used in both arms), demonstrated that triglyceride levels were significantly increased with stavudine, while remaining practically unchanged with tenofovir. 18 In the same study, LDL increased significantly more in the stavudine arm whereas HDL increased to a statistically significantly J INT ASSOC PHYSICIANS AIDS CARE 7(Supplement 1); 2008
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higher level in the tenofovir arm. Perhaps the takehome message is that cardiovascular risk should be determined in all HIV-infected patients. Baseline lipid profiles should be obtained, and antiretroviral agent selection should then be made based on cardiovascular risk profile as well as other factors. In addition to effects on lipid profiles, antiretroviral agents may have disparate effects on insulin resistance. Indinavir has been demonstrated to induce insulin resistance, 32 although insulin resistance has not been demonstrated for atazanavir. 33 Clearly, for patients with diabetes mellitus or glucose intolerance, prudent antiretroviral selection will include agents that do not cause insulin resistance, although admittedly, these data are lacking for some antiretroviral agents. NNRTIs have not been associated with insulin resistance, and in at least one published case, insulin sensitivity improved when a PI was replaced with nevirapine. 34 One last major metabolic issue that should be considered when selecting antiretroviral agents is the fat redistribution syndrome. Lipoatrophy is the loss of subcutaneous fat, most demonstrably in the cheeks of the face and in arms and legs. Thymidine analogues, stavudine and zidovudine, have been associated with lipoatrophy. In ACTG study 5142, lipoatrophy at 96 weeks (arbitrarily defined as >20% loss of extremity fat) occurred in 42% of patients receiving extendedrelease stavudine, 27% receiving zidovudine, and 9% receiving tenofovir. 35 However, combined analyses of all NRTIs demonstrated 96-week lipoatrophy rates of 32% for individuals randomized to the efavirenz + 2 NRTIs arm, compared with the 17% for lopinavir/ ritonavir + 2 NRTIs arm, and 9% in the NRTI sparing arm containing lopinavir/ritonavir + efavirenz. 35 Clearly, not only is the individual agent selection important, but the combination of agents is equally critical.
In conclusion, many efficacious agents are available for the construction of HAART regimens. Clearly, the first consideration is to ensure selection of antiretroviral agents to which the virus is sensitive. That said, when selecting an antiretroviral regimen, consideration should be given to optimizing adherence while minimizing drug toxicity. Individual cardiovascular risk profiles should be assessed for each patient, and specific comorbidities (eg, renal disease, diabetes mellitus) should be taken into account. Perhaps most important, a frank discussion of the patient's lifestyle, hopes, and fears should be conducted. Are hormonal contraceptives desirable in the case of a woman? How crippling would lipoatrophy be? Now more than ever before, we are able to customize antiretroviral therapy for patients, not only controlling the virus but also hopefully avoiding certain drug-related toxicities and thereby improving the quality of life of our patients.
